For the quarter ending 2025-09-30, ZLAB had -$15,114K decrease in cash & cash equivalents over the period. -$35,049K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -35,963 | -89,165 |
| Allowance for credit losses | -1 | 1 |
| Inventory write-down | 625 | 294 |
| Depreciation and amortization expenses | 3,901 | 7,193 |
| Amortization of deferred income | -1,330 | -2,661 |
| Share-based compensation | 16,923 | 32,773 |
| Loss from fair value changes of equity investment with readily determinable fair value | 0 | -1,912 |
| Losses on disposal of property and equipment | -24 | -211 |
| Noncash lease expenses | 1,872 | 5,377 |
| Debt issuance costs | 90 | 104 |
| Foreign currency remeasurement impact | 6,421 | 3,488 |
| Accounts receivable | -3,671 | 2,945 |
| Notes receivable | 8,612 | 6,611 |
| Inventories | 6,016 | 22,096 |
| Prepayments and other current assets | 2,643 | -854 |
| Other non-current assets | -548 | -51 |
| Accounts payable | -6,900 | 6,474 |
| Other current liabilities | 9,179 | -15,948 |
| Operating lease liabilities | -987 | -5,418 |
| Deferred income | -4 | 365 |
| Net cash used in operating activities | -32,044 | -92,723 |
| Proceeds from maturity of short-term investment | 0 | 330,000 |
| Proceeds from the sale of equity investment | 0 | 1,203 |
| Purchases of property and equipment | 3,005 | 4,419 |
| Proceeds from the sale of property and equipment | 37 | 48 |
| Acquisition of intangible assets | 1,081 | 3,621 |
| Net cash provided by (used in) investing activities | -4,049 | 323,211 |
| Proceeds from short-term debt | 61,215 | 124,349 |
| Repayment of short-term bank borrowings | 34,123 | 82,818 |
| Payments of debt issuance costs | 90 | 104 |
| Proceeds from exercises of stock options | 1,982 | 11,444 |
| Payments of public offering costs | 0 | 854 |
| Employee taxes paid related to net share settlement of equity awards | 8,191 | 27 |
| Net cash provided by financing activities | 20,793 | 51,990 |
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | 186 | 125 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -15,114 | 282,603 |
| Cash and cash equivalents at beginning of period | 550,781 | - |
| Cash and cash equivalents at end of period | 818,270 | - |
Zai Lab Ltd (ZLAB)
Zai Lab Ltd (ZLAB)